Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In
Selected by Dylan Ratigan.
Johnson and Roberts report that ARPA-H director Alicia Jackson publicly endorsed removal of the FDA's strongest warning from hormone-replacement therapies while financial disclosures showed at least $115,000 in stock, plus options of unknown value, in Evernow, a menopause-treatment platform she founded. Her portfolio also included stock in a biotechnology company receiving a preexisting $10 million ARPA-H award.
The story carefully separates appearance from proof: the FDA, not Jackson's agency, made the warning decision, and the article does not establish that she influenced it. Ethics specialists nevertheless said an official endorsement can constitute participation in a matter affecting personal finances. Evernow said she no longer held a financial interest, creating a factual dispute the reporting identifies rather than resolves.